Clinical Study

The Effect of Hyperbaric Oxygen Therapy on Functional Impairments Caused by Ischemic Stroke

Table 3

Effect of HBOT on functional impairments: repeated measures ANOVA.

DomainB1 versus B2B1,2 vs T1,2T1,2 vs Off and Follow-upOff vs Follow-up

Cognitive
 CVLT-IIF(1,5)=0.13, p=0.74F(1,5)=15.7, p=0.01F(1,4)=0.13, p=0.74F(1,4)=2.78, p=0.19
 Trails AF(1,5)=0.01, p=0.77F(1,5)=3.9, p=0.10F(1,4)=1.27, p=0.34F(1,4)=2.95, p=0.18
 COWATF(1,5)=2.59, p=0.17F(1,5)=4.0, p=0.09F(1,4)=0.31, p=0.61F(1,4)=0.003, p=0.96
 WMSF(1,5)=0.29, p=0.61F(1,5)=7.74, p=0.03F(1,4)=1.0, p=0.39F(1,4)=1.0, p=0.39
 DKEFSF(1,5)=0.11, p=0.78F(1,5)=3.6, p=0.11F(1,4)=0.07, p=0.81F(1,4)=0.11, p=0.76

Physical
 UEFMF(1,5)=0.65, p=0.46F(1,5)=9.6, p=0.03F(1,4)=6.5, p=0.06F(1,4)=0.24, p=0.64
 Gait VelocityF(1,4)=3.7, p=0.12F(1,4)=24.9, p=0.01F(1,3)=0.13, p=0.75F(1,3)=0.25, p=0.65

Quality of Life
 BDIF(1,5)=0.16, p=0.71F(1,5)=6.7, p=0.09F(1,4)=1.4, p=0.32F(1,4)=0.66, p=0.48
 SIS GlobalF(1,5)=8.4, p=0.03F(1,5)=7.2, p=0.04F(1,4)=2.0, p=0.23F(1,4)=1.67, p=0.27
 SIS EmotionalF(1,5)=0.56, p=0.28F(1,5)=3.0, p=0.14F(1,4)=0.83, p=0.41F(1,4)=0.51, p=0.51
 SIS ParticipationF(1,5)=0.005, p=0.9F(1,5)=3.7, p=0.11F(1,4)=0.56, p=0.50F(1,4)=0.08, p=0.80
 SIS PhysicalF(1,5)=2.8, p=0.17F(1,5)=4.2, p=0.09F(1,4)=0.96, p=0.38F(1,4)=1.0, p=0.36
 SleepF(1,5)=6.5, p=0.06F(1,5)=8.2, p=0.04F(1,4)=1.5, p=0.28F(1,4)=0.001, p=0.97
 SatisfactionF(1,5)=0.06, p=0.82F(1,5)=2.7, p=0.16F(1,4)=6.8, p=0.06F(1,4)=0.11, p=0.75

Biomarkers
 NSEF(1,5)=0.01, p=0.85F(1,5)=22.8, p=0.005F(1,4)=16.0, p=0.01F(1,4)=0.24, p=0.64
 GFAPF(1,5)=0.06, p=0.81F(1,5)=3.27, p=0.13F(1,4)=2.97, p=0.16F(1,4)=0.13, p=0.74
 IL-6F(1,5)=0.02, p=0.89F(1,5)=6.0, p=0.05F(1,4)=5.3, p=0.08F(1,4)=1.1, p=0.36
 TNF-aF(1,5)=0.04, p=0.85F(1,5)=14.2, p=0.013F(1,4)=18.4, p=0.01F(1,4)=0.34, p=0.59